David C. Oxley
Directeur/Bestuurslid bij TB Biosciences, Inc.
Profiel
David C.
Oxley is currently a Non-Executive Director at TB Biosciences, Inc. He previously held the position of Executive VP-Worldwide Sales & Marketing at Trinity Biotech Plc and Vice President-Emerging Market Sales at Plus Therapeutics, Inc. He will also serve as the President-International at Exopharm Ltd.
from 2021 to 2023.
Actieve functies van David C. Oxley
| Bedrijven | Functie | Begin |
|---|---|---|
TB Biosciences, Inc.
 TB Biosciences, Inc. Medical/Nursing ServicesHealth Services TB Biosciences, Inc. operates as a early stage development medical diagnostics company which develops a rapid point-of-care tuberculosis tests. It uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. The firm is using an array of patented peptides developed and exclusively licensed from the New York university school of medicine. The company was founded by Daniel Malamud, Susan Zolla-Pazner, Suman Laal, R. Sam Niedbala and William Abrams in May 2013 and is headquartered in Bethlehem, PA. | Directeur/Bestuurslid | 01-08-2013 |
Eerdere bekende functies van David C. Oxley
| Bedrijven | Functie | Einde |
|---|---|---|
| EXOPHARM | President | 01-01-2023 |
| TRINITY BIOTECH PLC | Verkoop & Marketing | - |
| PLUS THERAPEUTICS, INC. | Verkoop & Marketing | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PLUS THERAPEUTICS, INC. | Health Technology |
| TRINITY BIOTECH PLC | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
TB Biosciences, Inc.
TB Biosciences, Inc. Medical/Nursing ServicesHealth Services TB Biosciences, Inc. operates as a early stage development medical diagnostics company which develops a rapid point-of-care tuberculosis tests. It uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. The firm is using an array of patented peptides developed and exclusively licensed from the New York university school of medicine. The company was founded by Daniel Malamud, Susan Zolla-Pazner, Suman Laal, R. Sam Niedbala and William Abrams in May 2013 and is headquartered in Bethlehem, PA. | Health Services |
Exopharm Ltd.
 Exopharm Ltd. Pharmaceuticals: MajorHealth Technology Exopharm Ltd. engages in the research and development of biopharmaceutical drugs. The company was founded by Ian Dixon and Gregor Lichtfuss in 2013 and is headquartered in Camberwell, Australia. | Health Technology |
